FDA approves first medical treatment for Alzheimer’s in 18 years

The drug aducanumab, developed by the company Biogen, attacks the amyloid protein that builds up in the brain of Alzheimer’s patients. The drug is going on the market even though the FDA says there are “uncertainties regarding clinical benefits” and is requiring Biogen to do another clinical trial.